BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus 2009;2:309-11. [PMID: 25984024 DOI: 10.1093/ndtplus/sfp042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Seminars in Dialysis 2011;24:373-4. [DOI: 10.1111/j.1525-139x.2011.00913.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lord ML, Mcneill FE, Gräfe JL, Noseworthy MD, Chettle DR. Self-identified gadolinium toxicity: comparison of gadolinium in bone and urine to healthy gadolinium-based contrast agent exposed volunteers. Physiol Meas 2018;39:115008. [DOI: 10.1088/1361-6579/aaedc6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Acar T, Kaya E, Yoruk MD, Duzenli N, Senturk RS, Can C, Ozturk L, Tomruk C, Uyanikgil Y, Rybicki FJ. Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents. Jpn J Radiol 2019;37:458-65. [PMID: 30929137 DOI: 10.1007/s11604-019-00835-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK. Evaluating the Patient with Reported Gadolinium-Associated Illness. J Med Toxicol 2019;15:36-44. [PMID: 30499040 DOI: 10.1007/s13181-018-0689-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ngamcherdtrakul W, Morry J, Sangvanich T, Reda M, Bejan DS, Fryxell GE, Yantasee W. Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model. Sci Rep 2019;9:709. [PMID: 30679698 DOI: 10.1038/s41598-018-37348-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29:365-76. [PMID: 27053146 DOI: 10.1007/s10534-016-9931-7] [Cited by in Crossref: 336] [Cited by in F6Publishing: 265] [Article Influence: 56.0] [Reference Citation Analysis]
7 Alwasiyah D, Murphy C, Jannetto P, Hogg M, Beuhler MC. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study. J Med Toxicol 2019;15:121-7. [PMID: 30543028 DOI: 10.1007/s13181-018-0693-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]